Literature DB >> 4387028

Laboratory and clinical evaluation of rifampicin.

E Atlas, M Turck.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4387028

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


× No keyword cloud information.
  8 in total

1.  Lack of emergence of significant resistance in vitro and in vivo to the new azalide antibiotic azithromycin.

Authors:  J A Retsema; A E Girard; L A Brennan; C R Cimochowski; J A Faiella
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

2.  Bacteraemia due to a rifampicin-resistant strain of Bacteroides fragilis.

Authors:  D W Bullock; A J Webb; B I Duerden; V O Rotimi
Journal:  J Clin Pathol       Date:  1981-01       Impact factor: 3.411

3.  Evidence that rifampicin can be used safely for non-tuberculous diseases.

Authors:  G Acocella; W Brumfitt; J M Hamilton-Miller
Journal:  Thorax       Date:  1980-10       Impact factor: 9.139

Review 4.  Rifampicin: a review.

Authors: 
Journal:  Drugs       Date:  1971       Impact factor: 9.546

5.  Combination of minocycline and rifampicin against methicillin- and gentamicin-resistant Staphylococcus aureus.

Authors:  E Yourassowsky; M P van der Linden; M J Lismont; F Crokaert
Journal:  J Clin Pathol       Date:  1981-05       Impact factor: 3.411

6.  In vitro activity of combinations of antibiotics against Staphylococcus aureus resistant to gentamicin and methicillin.

Authors:  S Dixson; W Brumfitt; J M Hamilton-Miller
Journal:  Infection       Date:  1985 Jan-Feb       Impact factor: 3.553

Review 7.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

8.  Mechanism of Rifampicin Inactivation in Nocardia farcinica.

Authors:  Heba Abdelwahab; Julia S Martin Del Campo; Yumin Dai; Camelia Adly; Sohby El-Sohaimy; Pablo Sobrado
Journal:  PLoS One       Date:  2016-10-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.